SecBot SecBot
Biotech Drug Report Generated Nov 9, 2026

Gemini

REVB·REVELATION BIOSCIENCES, INC.
NEUTRAL
Drug Impact Rating6/10
Trial phase
Phase 1b completed; Phase 2/3 TITAN study planned
Time to market
Gemini is in Phase 1b/Phase 2 development. The Phase 2/3 TITAN study has not yet begun enrollment. If successful, potential FDA approval for AKI would likely be several years away, though the company reached an agreement with the FDA on an approval pathway in January 2026.
Why 6/10
The next hard, dated catalyst is the initiation and enrollment of the Phase 2/3 TITAN study in acute kidney injury (AKI), which the company said in August 2026 was on track to begin later in 2026. No PDUFA date or topline readout date has been announced yet. The TITAN study is the company's lead value driver, but REVB also has other pipeline programs, so the score is 6 rather than higher.
Actionable Insight NEUTRAL

Watch for the official start of the TITAN Phase 2/3 AKI study, which the company said in August 2026 was on track to begin later in the year. The company's cash runway extends into Q2 2027 per the Q3 2026 filing, so a financing event (dilutive offering) may be needed before the TITAN study produces data. Analyst consensus is bullish (6 Buy/Strong Buy, 1 Hold) with a mean price target of $124.25, but coverage is stale (no analyst action in 90+ days) and the stock trades near $3.89 after a 1-for-7 reverse split.

Price Chart

Loading chart...

Executive Summary

Gemini is Revelation Biosciences' lead drug candidate, a proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD) that acts as a TLR4 agonist to stimulate trained immunity. It is being developed for acute kidney injury (AKI) and chronic kidney disease (CKD). Phase 1 and Phase 1b studies have shown positive safety data and biomarker activity. The company reached an FDA agreement on an approval pathway for AKI in January 2026 and has selected a CRO for the planned Phase 2/3 TITAN study. However, REVB is a nano-cap stock (market cap around $2.5M) with no revenue, a going-concern risk flagged by analysts, and a history of reverse stock splits and dilutive financing. The stock trades near $3.89 after a 1-for-7 reverse split in October 2026, with a 52-week range of $3.08 to $40.60. Analyst consensus is bullish (6 Buy/Strong Buy, 1 Hold) with a mean price target of $124.25, but coverage is stale.

How It Works

Gemini is an intravenous drug that stimulates toll-like receptor 4 (TLR4), a protein on immune cells that acts like an alarm system. By briefly activating this alarm, Gemini "trains" or preconditions the innate immune system to respond more effectively to a subsequent stress such as kidney injury or infection. In CKD patients, the drug was shown to normalize cellular inflammation and restore immune function.

Trial Status

Phase 1 (RVL-HV02) in healthy volunteers completed in 2024, met the primary safety endpoint and showed statistically significant biomarker activity. Phase 1b PRIME study in Stage 3 and 4 chronic kidney disease (CKD) patients completed dosing in July 2025, with positive safety and activity data announced in September 2025 and additional positive data presented in March 2026. The company reached an FDA agreement on an approval pathway for AKI in January 2026, initiated GMP manufacturing, and selected Avance Clinical as CRO for the Phase 2/3 TITAN study in AKI in August 2026. The TITAN study was on track to begin later in 2026.

The Two-Sided Case

▲ Bull Case5
Phase 1 and Phase 1b studies met safety endpoints and showed statistically significant biomarker activity, including dose-dependent increases in IL-10 and normalization of cellular inflammation in CKD patients
FDA agreement on an approval pathway for AKI reached in January 2026, providing regulatory clarity
Independent market assessment estimated a $94 billion total addressable market for Gemini in Stage 2 and Stage 3 AKI
Analyst consensus is bullish: 6 Buy/Strong Buy ratings, 1 Hold, with a mean price target of $124.25 per share
GMP manufacturing has been initiated to support later-stage clinical development
▼ Bear Case5
The Phase 2/3 TITAN study has not yet begun enrollment; the company faces significant clinical and regulatory execution risk
REVB is a nano-cap with a market cap of approximately $2.5M, no revenue, and a going-concern risk flagged by analysts
Cash runway extends only into Q2 2027, and the company has a history of dilutive financings and reverse stock splits (three in the past year)
Institutional support is minimal: the largest tracked 13F holder (Geode Capital) trimmed its position by 60% in Q2 2026, and total institutional holdings are under $50,000
The stock has declined dramatically from its 52-week high of $40.60 to $3.89, and the October 2026 1-for-7 reverse split signals distress

Upcoming Catalysts

  • Initiation and enrollment start of the Phase 2/3 TITAN study in AKI (on track for later in 2026 per August 2026 guidance)
  • Potential need for additional financing before mid-2027 given cash runway
  • Any additional clinical data presentations at medical conferences

Source Filing

The SecBot filing or press-release report that triggered this drug report:

REVELATION BIOSCIENCES, INC. 8-K REVB ·Originating report

Sources · 8

Hover a chip for the title
1 sec.gov2 businesswire.com3 markets.financialcontent.com4 newswire.com5 msn.com6 newswire.com7 theglobeandmail.com8 seekingalpha.com